Polyrizon Ltd.

Polyrizon Ltd. (PLRZ) priced its initial public offering on Oct 30, 2024 at $4.38 per share, raising $4.2M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $18.4M. Aegis Capital was lead-left underwriter. Keren Law Firm and Greenberg Traurig advised the company and Sichenzia Ross Ference Carmel advised the underwriters.

Polyrizon Ltd. is a development-stage biotech company developing medical device hydrogels delivered as nasal sprays. Its Capture and Contain technology forms a thin barrier in the nasal cavity intended to act as a biological mask against viruses and allergens.

Status

IPO

Ticker

PLRZ

Exchange

Nasdaq Capital Market

Priced

Oct 30, 2024

IPO price

$4.38

Raised

$4.2M

Market cap at IPO price

$18.4M

First filed

Aug 10, 2022

Underwriters

Aegis Capital

Company counsel

Keren Law Firm and Greenberg Traurig

Underwriters' counsel

Sichenzia Ross Ference Carmel

Sector

Healthcare

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.